Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ATR CNSX:ATT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAptarGroup$140.59+0.8%$153.29$130.85▼$178.03$9.26B0.57375,705 shs333,409 shsATTAbattis BioceuticalsC$0.00C$0.05▼C$0.74N/AN/A1.42 million shsN/A10 Stocks Set to Soar in Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAptarGroup-0.38%-0.62%-11.63%-8.67%-2.64%ATTAbattis Bioceuticals0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATRAptarGroup4.7905 of 5 stars2.55.04.22.31.92.52.5ATTAbattis BioceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATRAptarGroup 3.00Buy$174.6024.19% UpsideATTAbattis Bioceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ATR, ENQ, BHMG, and ATT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/4/2025ATRAptarGroupWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$173.00 ➝ $153.008/4/2025ATRAptarGroupRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$182.00 ➝ $172.007/18/2025ATRAptarGroupWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$170.00 ➝ $173.007/15/2025ATRAptarGroupRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$175.00 ➝ $182.00(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATRAptarGroup$3.58B2.59$9.75 per share14.42$41.25 per share3.41ATTAbattis BioceuticalsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATRAptarGroup$374.54M$5.8124.2022.532.9010.84%15.39%8.60%10/23/2025 (Estimated)ATTAbattis BioceuticalsN/AN/A0.00N/AN/AN/AN/AN/AN/ALatest ATR, ENQ, BHMG, and ATT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/31/2025Q2 2025ATRAptarGroup$1.58$1.66+$0.08$1.67$954.06 million$966.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATRAptarGroup$1.801.28%N/A30.98%31 YearsATTAbattis BioceuticalsN/AN/AN/AN/AN/ALatest ATR, ENQ, BHMG, and ATT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/10/2025ATRAptarGroupquarterly$0.451.14%7/24/20257/24/20258/14/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATRAptarGroup0.201.210.83ATTAbattis BioceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATRAptarGroup88.52%ATTAbattis BioceuticalsN/AInsider OwnershipCompanyInsider OwnershipATRAptarGroup0.68%ATTAbattis BioceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATRAptarGroup13,50065.88 million65.43 millionOptionableATTAbattis BioceuticalsN/AN/AN/ANot OptionableATR, ENQ, BHMG, and ATT HeadlinesRecent News About These CompaniesAbattis Bioceuticals Stock Price HistoryMay 27, 2025 | investing.comAbattis Bioceuticals Corp. (ATTBF)August 2, 2024 | finance.yahoo.comB.C. investment dealer that oversaw suspicious, 'unprofitable' trades fined $150KFebruary 14, 2024 | richmond-news.comRB.C. investment dealer who oversaw suspicious, 'unprofitable' trades fined $150KFebruary 13, 2024 | vancouverisawesome.comVMinoxidil Price of 85 BrandsAugust 1, 2023 | medindia.netMAbattis Bioceuticals Stock (OTC:ATTBF), Quotes and News SummaryFebruary 23, 2023 | benzinga.comMalaysian Bulk Carriers Bhd (MBCB)July 26, 2022 | investing.comMetrc Enters Government Contract With The State Of South DakotaMarch 24, 2022 | benzinga.comCann American Cancels Over 3 Million Common SharesMarch 5, 2022 | benzinga.comLast Prisoner Project Calls For Support Of Rudi Gammo, Imprisoned For Operating A Medical Cannabis DispensarySeptember 1, 2021 | benzinga.comHollister Biosciences Stock Down Slightly On $17.6M Q2 2021 Revenue Report, $3.2M Of Adjusted EBITDAAugust 27, 2021 | benzinga.comMedia Sentiment Over Time Top HeadlinesView All HeadlinesWhy the American Eagle Stock Rally Isn't Just Speculation By Gabriel Osorio-Mazilli | July 28, 20253 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 20253 Stocks Riding the AI Data Center Buildout WaveBy Chris Markoch | August 6, 2025This Drone Stock Is on Sale Despite Big Army ContractBy Jeffrey Neal Johnson | July 31, 2025Invest in AI and Energy Infrastructure With These 5 ETFsBy Ryan Hasson | August 11, 2025ATR, ENQ, BHMG, and ATT Company DescriptionsAptarGroup NYSE:ATR$140.59 +1.11 (+0.80%) As of 02:14 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.AptarGroup, Inc. designs and manufactures a range of drug delivery, consumer product dispensing, and active material science solutions and services for the pharmaceutical, beauty, personal care, home care, and food and beverage markets. The company operates through Aptar Pharma, Aptar Beauty, and Aptar Closures segments. It also provides pumps for nasal allergy treatments; and metered dose inhaler valves for respiratory ailments, such as asthma and chronic obstructive pulmonary diseases; elastomer for injectable primary packaging components; and active material science solutions. In addition, the company offers dispensing pumps, closures, elastomeric components, and aerosol valves to the digital health solutions. It primarily sells its products and services in Asia, Europe, Latin America, and North America. AptarGroup, Inc. was incorporated in 1992 and is headquartered in Crystal Lake, Illinois.Abattis Bioceuticals CNSX:ATTAbattis Bioceuticals Corp. is a specialty biotechnology company. The Company aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. It operates through the segment of producing, licensing and marketing ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The Company, through its subsidiaries, develops and commercializes natural health (nutraceutical) products, and conducts research and development to create plant-based (botanical) intellectual property and ingredients for the pharmaceutical and bioceutical markets, among others. It offers products and services, such as botanical blends and formulas; cannabidiol ingredients; functional foods and beverages, and analytical services. It is focused on creating botanical formulations, medical marijuana and specialized health products for pain caused by inflammation, and mental ailments. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave Pulls Back Into a Screaming Buy Intel's White House Reset: From Political Storm to a Clearer Sky AST SpaceMobile on Track for Explosive Upside Oklo’s Stock Is Set up for a Correction—Buy It When It Bounces If Qualcomm Holds $145, Its Next Move Could Be Massive Alphabet Reclaims $200 Threshold—Bull Run Reignited? NFL and WWE Land on ESPN—The Impact on Disney and TKO Stocks Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access